STAT+: Definium’s LSD therapy eased anxiety in second large trial
The first wave of biotechs is nearing regulatory approval for psychedelic therapies, a class of treatments that appear to exert rapid benefits.
Definium Therapeutics announced on Monday that its LSD therapy, DT120, demonstrated efficacy in alleviating anxiety symptoms in a second large clinical trial. The 12-week study found that patients who received a 100-microgram dose of DT120 experienced a significant reduction of 9.8 points on the Hamilton Anxiety Rating Scale, in comparison to a 4.7-point decrease observed in the placebo group.
This difference of 5.1 points is on par with the outcome seen in Definium's initial late-stage anxiety study and surpasses the effects observed with many other anxiety treatments. While it's challenging to directly compare results across different studies, the rapid onset of benefits observed with psychedelic therapies like DT120 makes them an appealing option for patients who may require immediate relief.
Typically, traditional treatments such as antidepressants may take weeks to show any improvement, making Definium's psychedelic approach a promising alternative for those seeking faster results.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
